ASH 2023: Quadruple Treatment With Daratumumab Aids Progression-Free Survival in Multiple Myeloma
Additional benefit includes increased depth of response, with consistent findings across clinically relevant subgroups
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.